Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Bridging Health Equity Gaps: Creyos Launches an Even More Accessible Patient Experience
05. November 2024 08:00 ET
|
Creyos
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29. Oktober 2024 10:00 ET
|
Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29. Oktober 2024 07:48 ET
|
Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone
28. Oktober 2024 10:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These...
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
14. Oktober 2024 09:05 ET
|
Longeveron
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
07. Oktober 2024 09:05 ET
|
Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
02. Oktober 2024 09:05 ET
|
Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
30. September 2024 08:00 ET
|
Adaptive Research Inc
Adaptive Research announced it has begun enrolling patients in
AriBio’s Phase 3 POLARIS-AD Clinical Trial.
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
26. September 2024 09:05 ET
|
Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.